TipTraQ (TTQ001)

The TipTraQ (TTQ001) is a Class II prescription-only wearable breathing frequency monitor designed to diagnose sleep apnea in adults using a fingertip sensor. It employs a mobile app and cloud-based artificial intelligence to analyze physiological data, with its performance validated against gold-standard polysomnography and demonstrated substantial equivalence to legally marketed devices.

A communication dated February 3, 2025, addresses PranaQ Pte. Ltd. regarding their medical device, TipTraQ (TTQ001). This Class II device, identified as a Breathing Frequency Monitor, is a prescription-only wearable system designed to aid in the evaluation and diagnosis of sleep apnea in adult patients. It is intended for use in both home-based and clinical environments, utilizing a fingertip sensor to collect physiological data, which is then analyzed by a companion mobile app and cloud-based artificial intelligence. The device has been determined to be substantially equivalent to other legally marketed devices for its specified indications, allowing its marketing subject to various general and specific regulatory controls. The determination of equivalence was supported by extensive testing, including non-clinical and clinical performance studies. Non-clinical tests encompassed bench testing for pulse rate accuracy, comprehensive software verification and validation, electrical and mechanical safety assessments, electromagnetic compatibility, and biocompatibility evaluations in accordance with relevant standards. Clinical performance was validated through an SpO2 study demonstrating the device's accuracy in oxygen saturation measurement, and a sleep validation study which compared TipTraQ's performance against gold-standard polysomnography, meeting predefined acceptance criteria for parameters such as total sleep time, sleep stages, and apnea-hypopnea index (AHI). These studies affirm that any differences in the device's characteristics do not raise new questions of safety or effectiveness.

AI Regulatory Concerns

Powered by

Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.

• Q1. What specific clinical scenarios or patient populations might benefit most from TipTraQ's home-based monitoring capabilities compared to traditional in-clinic PSG?; How does the cloud-based artificial intelligence algorithm handle artifacts or noisy data from the fingertip sensor in a home environment, and what is its sensitivity and specificity in detecting sleep apnea events?; Are there any reported limitations or contraindications for TipTraQ use, particularly concerning different skin types, comorbidities, or concurrent medications that might affect sensor accuracy?; What is the long-term data on user adherence and patient satisfaction with the TipTraQ wearable system for extended sleep monitoring?; Beyond AHI, total sleep time, and sleep stages, what other physiological parameters does the AI analyze, and could these provide additional insights into sleep disordered breathing or other co-morbid conditions?